What if something better comes along before rapamycin has a chance to go truly mainstream? Interest and progress in longevity is accelerating. It might be that we never see rapamycin go mainstream, but perhaps another mTOR1 inhibitor (this is a good thing despite our attachment to rapamycin).
I’m eagerly awaiting the first part of the data from the 601 mTOR inhibitor screening 
1 Like
KarlT
#43
Better would also have to be cheaper to displace Rapamycin as the leader.
1 Like
That will come in time and with scaling. We shouldn’t sacrifice progress for pragmatism.
Anyway that was just my own bold prediction.
1 Like
